Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept + Methotrexate in Very Early RA (AVERT)
NCT01142726Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2010
- Primary completion
- Sep 2013
- Modality
- Fc-Fusion Proteins
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of abatacept in rheumatoid arthritis (RA) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Percentage of Participants Who Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein Criteria at 18 months. Started Dec 2010; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01142726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01142726.